Patients with muscle-invasive bladder cancer (MIBC) who undergo surgery within 14 days of diagnosis have significantly better survival rates than those who wait longer, a recent study suggests. Researchers found that shorter waiting times alone were linked to a 60% lower risk of dying from bladder cancer.
The study, published in Cancer Management and Research, followed 83 patients who underwent a laparoscopic radical cystectomy, a minimally invasive surgery to remove the bladder. To ensure the data focused strictly on the impact of scheduling delays, the study included only patients who proceeded directly to surgery without receiving chemotherapy beforehand.
The researchers used a 14-day cutoff to compare outcomes, which was the median wait time for the entire group. This interval began after the patients underwent a transurethral resection of bladder tumor (TURBT), a procedure used to both diagnose cancer and remove as much of the tumor as possible from the bladder wall.
The study revealed a significant difference in overall survival outcomes based on how quickly patients underwent cystectomy. Among those who underwent the procedure within 14 days, 83.3% survived the first year, compared with 68.3% among those who waited longer than two weeks.
When focusing specifically on deaths caused by bladder cancer, the trend remained consistent. Nearly 79% of patients in the short-wait group reached the one-year mark, while that number decreased to 63.4% for patients with longer wait times.
Read more about bladder cancer treatment and care
While timing was critical, other factors also influenced patient prognosis. Smoking was identified as a major risk factor, increasing the risk of poor outcomes by more than five times. Larger tumor size and a patient’s overall physical activity level also played significant roles. The study found that even minor limitations in activity were linked to poorer survival.
While it may seem surprising, some patients with advanced stage (pT4) cancer showed slightly better survival rates even with longer delays. This could be explained by the small size of this group and the fact that these individuals, due to the advanced nature of their disease, often receive more intensive and frequent medical monitoring.
“These findings suggest that expeditious surgery may confer a meaningful survival benefit, potentially by limiting the window for micrometastatic progression,” the authors concluded. However, they noted a multidisciplinary, patient-centered framework is essential to balance early intervention with selective delays for frail individuals requiring medical optimization.
Sign up here to get the latest news, perspectives, and information about bladder cancer sent directly to your inbox. Registration is free and only takes a minute.